Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence
Ailsa J. Christiansen(University Hospital Zurich), Thomas Hermanns(University of Cologne), Anja Lorch(University Hospital of Zurich), Aashil A. Batavia(Novartis (Switzerland)), Christian Rothermundt, Arnoud J. Templeton(University of Basel), Richard Cathomas(Kantonsspital Graubünden), Anita Hirschi-Blickenstorfer(Klinik Hirslanden), Josias Bastian Grogg(Wroclaw Medical University), Holger Moch(University of Basel), Silke Gillessen(Institute of Oncology Research), João Lobo(Universidade do Porto), Christian D. Fankhauser(University of Zurich)
Cited by 8
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
|Nature Genetics|1997|1.5k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996